Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.05)
# 4,319
Out of 4,944 analysts
16
Total ratings
15.38%
Success rate
-47.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $3 | $0.29 | +934.48% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $0.81 | +1,873.36% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $1.72 | +423.26% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $2.15 | +272.09% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $10.66 | +838.09% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $2.13 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $0.40 | +37,400.00% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $3.20 | +368.75% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $3.47 | +505.19% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $33.51 | +168.58% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $3.41 | +8,990.91% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $6.45 | +521,234.37% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $3
Current: $0.29
Upside: +934.48%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $0.81
Upside: +1,873.36%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $1.72
Upside: +423.26%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $2.15
Upside: +272.09%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $10.66
Upside: +838.09%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.13
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $0.40
Upside: +37,400.00%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $3.20
Upside: +368.75%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $3.47
Upside: +505.19%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $33.51
Upside: +168.58%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $3.41
Upside: +8,990.91%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $6.45
Upside: +521,234.37%